Zimmer Biomet Holdings (XSWX:ZBH) Long-Term Debt: CHF4,956 Mil (As of Mar. 2026)


XSWX:ZBH Zimmer Biomet Holdings Inc XSWX:ZBH
69 GF Score
Price CHF69.50
GF Value CHF97.75
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Zimmer Biomet Holdings Long-Term Debt?

Zimmer Biomet Holdings XSWX:ZBH 69 Long-Term Debt is CHF4,956 Mil as of Mar. 2026. GuruFocus rates XSWX:ZBH with a GF Score™ of 69/100 and a GF Value™ of CHF97.75 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Zimmer Biomet Holdings's Long-Term Debt for the quarter that ended in Mar. 2026 was CHF4,956 Mil.

Zimmer Biomet Holdings's quarterly Long-Term Debt declined from Sep. 2025 (CHF5,981 Mil) to Dec. 2025 (CHF5,524 Mil) and declined from Dec. 2025 (CHF5,524 Mil) to Mar. 2026 (CHF4,956 Mil).

Zimmer Biomet Holdings's annual Long-Term Debt increased from Dec. 2023 (CHF4,210 Mil) to Dec. 2024 (CHF4,763 Mil) and increased from Dec. 2024 (CHF4,763 Mil) to Dec. 2025 (CHF5,524 Mil).

Zimmer Biomet Holdings  (XSWX:ZBH) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Zimmer Biomet Holdings Long-Term Debt Related Terms

Zimmer Biomet Holdings Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Zimmer Biomet Holdings's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zimmer Biomet Holdings Long-Term Debt Chart

Zimmer Biomet Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,032.07 4,799.79 4,209.76 4,762.57 5,524.11

Zimmer Biomet Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,810.82 5,491.13 5,980.78 5,524.11 4,956.13
XSWX:ZBH
69GF Score
Zimmer Biomet Holdings Inc XSWX:ZBH
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of CHF4,956 Mil mean?
Zimmer Biomet Holdings (XSWX:ZBH) has a Long-Term Debt of CHF4,956 Mil as of Mar. 2026.
Is Zimmer Biomet Holdings' Long-Term Debt too high?
Zimmer Biomet Holdings' current Long-Term Debt is CHF4,956 Mil. Overall, Zimmer Biomet Holdings has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Long-Term Debt compare to STE and PEN?
Zimmer Biomet Holdings' Long-Term Debt of CHF4,956 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Zimmer Biomet Holdings's current Long-Term Debt is CHF4,956 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (XSWX:ZBH) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF97.75, compared to a current price of CHF69.50 — trading 28.9% below its estimated fair value. The current Long-Term Debt is CHF4,956 Mil. Zimmer Biomet Holdings' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current Long-Term Debt is CHF4,956 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?

Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued. The current stock price of CHF69.50 is trading 28.9% below its estimated GF Value™ of CHF97.75. GuruFocus considers Zimmer Biomet Holdings to be Modestly Undervalued.

Key valuation signals for XSWX:ZBH:

  • Long-Term Debt: CHF4,956 Mil
  • GF Value™: CHF97.75 vs. price of CHF69.50 (28.9% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zimmer Biomet Holdings Business Description

Address 345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
69GF Score

Get the complete analysis for XSWX:ZBH

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF69.50
Price
CHF97.75
GF Value